- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
FDA Clears New AI Software for MRI Detection of Prostate Cancer
The ProstatID, an adjunctive artificial intelligence software that radiologists can utilize with traditional magnetic resonance imaging (MRI), reportedly measures prostate gland volume, and suggests PI-RADS scoring of suspicious lesions.
An emerging artificial intelligence (AI) software program that may enhance the efficiency and accuracy of prostate cancer diagnosis has received 510(k) clearance from the Food and Drug Administration (FDA).
Through computer-aided detection (CAD), ProstatID™ (Bot Image) offers a colorized translucent overlay of two-dimensional axial T2 magnetic resonance imaging (MRI) to identify soft tissue lesions that may warrant closer inspection for potential malignancy. The ProstatID algorithm also utilizes the Prostate Imaging Reporting and Data System (PI-RADS) to score the cancer probability of suspicious lesions, according to Bot Image. The company noted that two internal studies showed improved accuracy and a reduced false positive rate with the use of ProstatID.
While other technologies have enhanced formatting and segmentation of MRI images of the prostate, Bot Image said ProstatID is a significant advance for the diagnosis of prostate cancer.
“Prostate cancer screening and detection methods adoption (have) changed little over the past 30 years despite the mountain of evidence pointing to the efficacy of superior technologies and the futility of the old methods,” noted Bot Image founder and CEO Randall W. Jones, Ph.D. “Sadly, this has resulted in the unnecessary and premature deaths of countless numbers of men in the (United States) alone. ProstatID represents an exciting step in the fight to save lives.”
Bot Image noted that ProstatID is available to radiologists as a software as a service (SaaS) tool, which provides secure, HIPAA compliant connectivity between a cloud-based ProstatID server and a facility’s radiology department server.
AI Mammography Platform Shows Promising Results for Detecting Subclinical Breast Cancer
October 3rd 2024Mean artificial intelligence (AI) scoring for breasts developing cancer was double that of contralateral breasts at initial biennial screening and was 16 times higher at the third biennial screening, according to a study involving over 116,000 women with no prior history of breast cancer.
Study Shows MRI-Targeted Biopsies Reduce Overdiagnosis of Clinically Insignificant PCa by 57 Percent
September 27th 2024Omitting biopsy procedures in men with PSA levels > 3 ng/ml and negative MRI findings for prostate cancer (PCa) was associated with significantly lower risks of diagnosing clinically insignificant PCa in comparison to the use of systematic biopsy, according to an approximately four-year study of over 13,000 men who had prostate cancer screening.
PSMA PET/CT or mpMRI: Which is Better for Diagnosing Biochemical Recurrence of PCa?
September 24th 2024A new meta-analysis found that PSMA PET/CT offers a 12 percent higher positivity rate for detecting biochemical recurrence of PCa and a 19 percent higher positivity rate for identifying lymph node metastasis in comparison to mpMRI.
